Gilead Sciences agreed to acquire Repare Therapeutics' polymerase theta (Polθ) ATPase inhibitor RP-3467 for up to $30 million ($25 million upfront plus $5 million upon technology transfer completion). The deal increases Repare's cash balance, raising the estimated cash payment to shareholders to approximately $2.20 per share. RPTX shares surged ...

Law firm Monteverde & Associates is investigating potential shareholder class action lawsuits for four companies undergoing mergers, including Repare Therapeutics, Forge Global Holdings, CSG Systems International, and First Citizens Bancshares.

Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving proposed mergers and acquisitions.

Law firm Monteverde & Associates is investigating potential merger and acquisition deals for several companies, examining the fairness of proposed transactions and potential shareholder implications.

Repare Therapeutics will be acquired by XenoTherapeutics, with shareholders receiving $1.82 per share and a contingent value right. The transaction is expected to close in Q1 2026.